2025-07-23 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc (HIMS), incorporating the provided data and focusing on actionable insights.

**Equity Report: Hims & Hers Health Inc (HIMS)**

**1. Performance Overview:**

*   **Company Description:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions.

*   **Relative Performance:**
    *   HIMS Cumulative Return: 177.40%
    *   VOO (S&P 500) Cumulative Return: 65.67%
    *   Spread (HIMS - VOO): 98.3
    *   Relative Spread Position: 49.5 (Indicates HIMS is currently positioned near the middle of its historical spread range vs. VOO).

    *   **Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the period. However, the relative spread position suggests that, while still positive, its outperformance is not currently at its historical peak.

*   **Alpha/Beta Analysis:**

    | Year       | CAGR     | MDD   | Alpha    | Beta   | Cap(B) |
    |------------|----------|-------|----------|--------|--------|
    | 2019-2021  | -46.0%   | 51.0% | -84.0%   | -0.0   | 1.5    |
    | 2020-2022  | -15.0%   | 72.1% | -17.0%   | -0.0   | 1.4    |
    | 2021-2023  | -51.0%   | 72.1% | -69.0%   | -0.1   | 2.0    |
    | 2022-2024  | 127.0%   | 78.4% | 101.0%   | -0.1   | 5.4    |
    | 2023-2025  | 172.0%   | 78.4% | 123.0%   | -0.1   | 11.2   |

    *   **Analysis:** The Alpha/Beta analysis reveals some interesting trends.  While recent periods (2022-2025) show very strong CAGR and positive Alpha (outperformance), earlier periods (2019-2023) showed negative CAGR and negative Alpha (underperformance).   The Beta is consistently negative, approaching zero, suggesting HIMS price moves are negligibly correlated with overall market movement represented by the S&P500. The Maximum Drawdown (MDD) is high across all periods, indicating significant price volatility and risk.
  

**2. Recent Price Action:**

*   Current Price: $50.01
*   Previous Close: $47.6
*   Change: 5.06% (Significant positive change)
*   5-day Moving Average: $49.97
*   20-day Moving Average: $48.71
*   60-day Moving Average: $51.25

*   **Analysis:** The stock has recently experienced a significant price increase, as evidenced by the 5.06% change and the current price exceeding both the 5-day and 20-day moving averages. The price is approaching the 60-day moving average ($51.25), suggesting a potential resistance level. The gap between the 5-day and 20-day moving averages indicates strong upward momentum.

**3. Technical Indicators and Outlook:**

*   Market Risk Indicator (MRI): 0.3359 (Low Risk)
*   RSI: 54.62 (Neutral)
*   PPO: 0.115
*   Hybrid Signal: Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   Recent (20-day) Relative Divergence Change: -6.6 (Negative - Short-term decline)
*   Expected Return: -18.8% (Long-term, relative to S&P 500)

*   **Analysis:** The MRI indicates a low-risk environment. The RSI is neutral, suggesting neither overbought nor oversold conditions. The PPO is slightly positive, indicating the short-term moving average is a little bit above the long-term moving average. The hybrid signal suggests a "Buy" signal (80% of cash), but with caution due to the MRI level. The negative change in relative divergence suggests potential short-term weakness.  The negative expected return suggests that, from the current valuation, long-term returns *may* underperform the S&P 500, based on the model's assumptions.

**4. Recent News & Significant Events:**

*   **News Summary:** Recent news highlights business developments, regulatory changes, market volatility, analyst discussions, and a need for investors to monitor company announcements.

*   **Analysis:** The news summary suggests that HIMS is currently subject to market attention and its stock price is influenced by both internal and external factors.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2024-05-06 | 0.05 | 0.28 B$   |
| 2025-05-05 | 0.05 | 0.28 B$   |

*   **Analysis:** The table shows increasing revenue over the past quarters. EPS (Earnings Per Share) fluctuates, but the latest EPS and revenue both indicate positive growth.

**6. Financial Information:**

*   **Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $0.59B   | 73.50%        |
| 2024-12-31 | $0.48B   | 76.81%        |
| 2024-09-30 | $0.40B   | 79.16%        |
| 2024-06-30 | $0.32B   | 81.30%        |
| 2024-03-31 | $0.28B   | 82.36%        |

*   **Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-03-31 | $0.55B   | 9.01%  |
| 2024-12-31 | $0.48B   | 5.46%  |
| 2024-09-30 | $0.44B   | 17.18% |
| 2024-06-30 | $0.36B   | 3.67%  |
| 2024-03-31 | $0.34B   | 3.23%  |

*   **Analysis:** Revenue is consistently growing. Profit Margins were decreasing over the period, but this period saw them decreasing. Equity is also generally increasing, showing growth in the company's asset base. ROE (Return on Equity) is quite volatile and is increasing in the recent term.

**7. Summary and Conclusion:**

HIMS has demonstrated strong growth and has significantly outperformed the S&P 500 over the past few years. Recent price action is positive, but the negative relative divergence and potentially negative long-term expected return suggest that the stock may be overvalued or due for a correction.

The financial data reveals increasing revenue and growing equity, but the profit margin should be monitored for sustainability. The analyst commentary on recent news also points to risks and volatility which needs further investigation.

**Recommendation:**

Given the recent surge in price and negative expected return, investors should exercise caution and conduct thorough due diligence. Consider waiting for a potential pullback or consolidation before establishing a long position. The positive earnings and revenue growth are encouraging, but the volatility, potential overvaluation, and competitive pressures in the telehealth space warrant a cautious approach. Monitor company announcements and industry news closely for further insights.
